Back to Search
ROBERT VESCIO, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1962509216IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
G063211(CA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
UNIVERSITY OF CALIFORNIA, SAN DIEGO SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.
PMID 10673673·Bone Marrow Transplant·2000
3-trial
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
PMID 19622094·Br J Haematol·2009
3-trial
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
PMID 19498019·Blood·2009
3-trial
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
PMID 19471019·Blood·2009
3-trial
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
PMID 18509352·Leukemia·2008
8-other
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
PMID 18463870·Ann Hematol·2008
3-trial
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
PMID 18000495·Clin Adv Hematol Oncol·2007
8-other
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
PMID 16418495·J Clin Oncol·2006
3-trial
Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
PMID 14615454·J Clin Oncol·2003
6-review
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
PMID 14556685·Clin Lymphoma·2003
3-trial
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
PMID 12631619·Clin Cancer Res·2003
8-other
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
PMID 12412821·J Clin Pharmacol·2002
3-trial
Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.
PMID 12377412·Cancer Genet Cytogenet·2002
8-other
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
PMID 11740821·Semin Oncol·2001
6-review
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
PMID 11533101·J Clin Oncol·2001
3-trial
Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM).
PMID 11480570·Leukemia·2001
8-other
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
PMID 11297237·Clin Cancer Res·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD, C-2000
LOS ANGELES, CA 90048 - Phone
- (310) 423-1825
Quick Facts
- NPI
- 1962509216
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile